Replies to post #242534 on Biotech Values

[vinmantoo]

NIH wants_to_study longer treatment_course for Paxlovid:

That could be problematic for the high risk groups that are the prime target for the PFE regimen given it increases the half-life and increases levels of other drugs patients tested.

The Paxlovid treatment course under the existing EUA is 5 days. However, this is not because 5 days is necessarily optimal, but rather because 5 days is how long the treatment was in PFE’s phase-3 clinical trial.

I wonder if ENTA will be adding a longer regimen for one of its EDP-235 phase 2/3 trials?

[mouton29]

Not directly related to the 5 v longer question but I find it difficult to believe they any such trial would be permitted to exclude vaccinated or previously infected (as EPIC-SR now does) given that that’s got to be a large percentage of the population Paxlovid is being given to in the real world.

[DewDiligence]

(ENTA)—Re: COVID rebound following Paxlovid treatment

As case reports of COVID rebound following Paxlovid treatment continues to accumulate, the CDC formally recommends an isolation period for those who become re-infected:

https://emergency.cdc.gov/han/2022/han00467.asp

COVID-19 Rebound After Paxlovid Treatment

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and the public on the potential for recurrence of COVID-19 or “COVID-19 rebound.”

…Paxlovid treatment helps prevent hospitalization and death due to COVID-19. COVID-19 rebound has been reported to occur between 2 and 8 days after initial recovery and is characterized by a recurrence of COVID-19 symptoms or a new positive viral test after having tested negative.

…Regardless of whether the patient has been treated with an antiviral agent, risk of transmission during COVID-19 rebound can be managed by following CDC’s guidance on isolation, including taking other precautions such as masking.